Study: Ditch the contrast agent in PET/MRI scans in children with lymphoma
F-18 FDG-PET/MRI scans without the use of a contrast agent should be the top choice for imaging children suffering from lymphoma, according to research presented recently at RSNA in Chicago. In a scientific session held November 30, Nils-Martin Bruckmann, MD, of University Hospital Düsseldorf in Germany, discussed a study that evaluated FDG-PET/MRI scans with and without the use of a contrast agent in children with newly diagnosed disease. The study authors found the contrast agent made no diagnostic difference.“The use of MRI contrast agents in F-18 FDG-PET/MRI examinations has no additional positive benefit for primar...
Source: AuntMinnie.com Headlines - December 7, 2023 Category: Radiology Authors: Will Morton Tags: Molecular Imaging Source Type: news
Radioimmunotherapy Tops ASCT in R/R Follicular Lymphoma Radioimmunotherapy Tops ASCT in R/R Follicular Lymphoma
A new trial from Italy challenges a decades-old assumption that autologous stem cell transplant is more effective than radioimmunotherapy for consolidation after follicular lymphoma relapse.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 5, 2023 Category: Drugs & Pharmacology Tags: Hematology-Oncology Source Type: news
Rituximab Maintenance Boosts Survival for Older Adults With MRD-Negative MCL
(MedPage Today) -- Maintenance therapy with rituximab yielded better survival outcomes for older patients with minimal residual disease (MRD) negativity after induction therapy for mantle cell lymphoma (MCL), results from the European Mantle Cell... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 5, 2023 Category: Hematology Source Type: news
CAR-T Therapies Not Cost-Effective for Diffuse Large B-Cell Lymphoma
MONDAY, Dec. 4, 2023 -- For patients with diffuse large B-cell lymphoma (DLBCL), the chimeric antigen receptor T-cell therapies (CAR-T) axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are not cost-effective, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 4, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves Pirtobrutinib for Previously Treated CLL/SLL FDA Approves Pirtobrutinib for Previously Treated CLL/SLL
The approval is the second this year for the reversible, highly selective kinase inhibitor following a January approval in mantle cell lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 4, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Non-Covalent BTK Inhibitor Approved for CLL
(MedPage Today) -- The FDA expanded the label of pirtobrutinib (Jaypirca) to include the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) following two prior lines of therapy, the agency announced on Friday.
An... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 4, 2023 Category: Hematology Source Type: news
PET/CT predicts patient responses to CAR-T cell therapy
F-18 FDG-PET/CT scans may predict outcomes in patients with large B cell lymphoma undergoing chimeric antigen receptor (CAR) T-cell therapy, according to a presentation delivered November 30 at RSNA. Doris Leithner, MD, of Memorial Sloan-Kettering Cancer Center in New York City, presented a study in which researchers explored whether F-18 FDG-PET/CT imaging features acquired prior to treatment with CAR T-cell therapy were related to patient outcomes. They found the imaging features were strongly associated with death, relapse, and disease progression.“Our results demonstrate that quantitative PET imaging features in LBCL...
Source: AuntMinnie.com Headlines - December 4, 2023 Category: Radiology Authors: Will Morton Tags: Nuclear Radiology Source Type: news
Misdiagnoses Among Challenges in Managing Cutaneous Lymphoma Misdiagnoses Among Challenges in Managing Cutaneous Lymphoma
Although predictive tools to identify those at risk of disease progression are in their infancy, the development of such tools is crucial for improving patient outcomes.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 2, 2023 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
Year in Review: Follicular Lymphoma
(MedPage Today) -- Credit: Patho
Studies demonstrating high response rates and manageable safety profiles, along with FDA approvals, have supported bispecific antibodies as promising treatment options for follicular lymphoma.
At the start... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 1, 2023 Category: Hematology Source Type: news
Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
The first and only non-covalent (reversible) BTK inhibitor, Jaypirca has been shown to extend the benefit of BTK inhibition
In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have received at least two lines of therapy, including a BTK... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 1, 2023 Category: Drugs & Pharmacology Source Type: news
FDA Investigates Secondary Cancers From CAR T-Cell Therapies FDA Investigates Secondary Cancers From CAR T-Cell Therapies
The FDA has determined that the risk for lymphoma and other T-cell cancers may apply to approved BCMA- and CD-19 –directed CAR T-cell immunotherapies.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 28, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Psychological Distress Reported for Indolent Non-Hodgkin Lymphomas
TUESDAY, Nov. 21, 2023 -- Patients with indolent non-Hodgkin lymphomas (iNHL) report considerable psychological distress, according to a study published online Nov. 3 in The Oncologist.Richard A. Newcomb, M.D., from Massachusetts General Hospital... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 21, 2023 Category: Pharmaceuticals Source Type: news
Apixaban Prophylaxis Fails to Reduce Clots in Pediatric ALL
(MedPage Today) -- Prophylaxis with apixaban (Eliquis) failed to reduce the rate of venous thromboembolism (VTE) in children with newly diagnosed acute lymphoblastic leukemia or lymphoma, according to results from the phase III randomized PREVAPIX... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 21, 2023 Category: Cardiology Source Type: news
Poor Physical Function Persists in Childhood Cancer Survivors
MONDAY, Nov. 20, 2023 -- Despite changes in therapy, the prevalence of poor physical function has remained steady among childhood survivors of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 20, 2023 Category: Pharmaceuticals Source Type: news
Was This a Recurrence of Non-Hodgkin ’s Lymphoma or Something Else?
“Go to the emergency room,” the doctor told him after hearing of his trip and fever, rash and whole-body weakness. “You need to be seen.” (Source: NYT Health)
Source: NYT Health - November 20, 2023 Category: Consumer Health News Authors: Lisa Sanders, M.D. Tags: Chikungunya Virus Non-Hodgkin ' s Lymphoma Lyme Disease Joints (Body Part) Source Type: news
